恩杂鲁胺治疗患者潜在药物相互作用的高 prevalence 与数据库间差异
该回顾性研究评估了105例接受恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者的潜在药物相互作用(DDI)。结果显示,三种国际药物相互作用数据库对潜在DDI的标记率与严重程度分级差异很大,且患者合并用药多,潜在DDI普遍存在。
要点
- 恩杂鲁胺患者合并用药多(中位11种),潜在DDI常见(中位4种/患者,Lexicomp)。
- 不同数据库对DDI的标记率和分级差异显著,需谨慎解读。
- 质子泵抑制剂和中枢神经系统抑制剂是常见的潜在DDI药物类别。
核心结论
- 接受恩杂鲁胺治疗的mCRPC患者中潜在DDI普遍存在,且不同药物相互作用数据库的收录和分级差异很大。
研究设计与样本
- 回顾性队列研究,通过药房记录回顾性获取105例开始恩杂鲁胺治疗的mCRPC患者的个体用药史。
主要发现
- 205种不同合并用药中,56种被至少一个数据库标记为潜在DDI。
- Lexicomp、Micromedex和荷兰药物数据库分别标记了85%、54%和32%的潜在DDI。
- 85%的DDI被归类为严重(major)。
- 每位患者合并用药中位数为11种(范围1-26)。
- 每位患者潜在DDI数量中位数(范围):Lexicomp 4(0-10),Micromedex 1(0-5),荷兰数据库0(0-2)。
临床怎么用
- 医生、护士和药师应意识到恩杂鲁胺治疗中潜在DDI的高风险,可能需要加强监测或调整治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Metastatic castration-resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore at increased risk of complications due to drug-drug interactions (DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide. METHODS: We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting. Potential DDIs were analysed using two international drug interaction compendia: Lexicomp® and Micromedex® , and the Dutch drug database. Two potential pharmacodynamic DDIs were analysed. RESULTS: A total of 105 records were evaluated for potential DDIs with enzalutamide. Of 205 different co-medications, 56 were flagged by at least one of the three compendia: Lexicomp, Micromedex and the Dutch drug database flagged for potential DDIs in 85%, 54% and 32%, respectively. Eighty-five per cent of DDIs were classified as major. The median number of co-medications per patient was 11 (range 1-26). The median (range) number of interactions per patient was 4 (0-10), 1 (0-5) and 0 (0-2) for Lexicomp, Micromedex and the Dutch drug database, respectively. In 23% and 45% of all patients, a potential DDI was found with PPIs and CNS depressants, respectively. CONCLUSIONS: A high prevalence of potential DDIs was found. The inclusion and grading of potential DDIs was highly variable between the three drug interaction compendia. Physicians, nurses and pharmacists should be aware of this potential problem, which might require intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.
引用
- Benoist GE, van Oort IM, Smeenk S, et al. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br J Clin Pharmacol. 2017. PMID: 28881501. doi:10.1111/bcp.13425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。